Brain stimulation reduces impulsive choices
- Trial ID
- NCT06485986
- Official Title
- Frontosubthalamic Network Dynamics and Their Modulation During Impulse Control and Decision Making in Parkinson's Disease
- Goal
- Brain stimulation reduces impulsive choices
- Phase
- NA
- Status
- RECRUITING
- Sponsor
- University of Oxford
- Study Type
- INTERVENTIONAL
- Enrollment
- 20 participants
- Conditions
- Parkinson Disease, Impulse Control Disorder
- Interventions
- DBS on/off
Plain-Language Summary
The team wants to map how the fronto‑subthalamic brain network controls decision making and impulsive behaviours in Parkinson's, and to see how stimulating the subthalamic nucleus changes those brain signals and impulse control. People who already have STN deep brain stimulation will do decision and impulse‑control tasks while brain activity is recorded with MEG, with DBS switched on and off so researchers can compare network dynamics. DBS changes electrical activity in the subthalamic nucleus, which can alter both motor circuits and decision‑making pathways; because DBS is usually used alongside levodopa, participants will delay their morning dopamine dose for up to four hours so the team can separate stimulation effects from medication effects. The trial is for adults 18 and over with Parkinson's who already have STN electrodes and are on dopamine replacement, with or without impulse control disorders, who can sit in an MEG scanner and safely delay their morning meds.
Locations
- John Radcliffe Hospital, Oxford, United Kingdom
Frequently Asked Questions
- What is this trial testing?
- This trial is studying DBS on/off. The team wants to map how the fronto‑subthalamic brain network controls decision making and impulsive behaviours in Parkinson's, and to see how stimulating the subthalamic nucleus changes those brain signals and impulse control. People who already have STN deep brain stimulation will do decision and impulse‑control tasks while brain activity is recorded with MEG, with DBS switched on and off so researchers can compare network dynamics. DBS changes electrical activity in the subthalamic nucleus, which can alter both motor circuits and decision‑making pathways; because DBS is usually used alongside levodopa, participants will delay their morning dopamine dose for up to four hours so the team can separate stimulation effects from medication effects. The trial is for adults 18 and over with Parkinson's who already have STN electrodes and are on dopamine replacement, with or without impulse control disorders, who can sit in an MEG scanner and safely delay their morning meds.
- Who can participate?
- Participants must be at least 18 Years.
- Where is this trial located?
- This trial is recruiting at 1 location.
- Does it cost anything to join?
- No. There is no cost to participate. Study-related care and treatment are provided at no charge.
- How long does the trial last?
- This trial is estimated to last approximately 2 years and 2 months.